Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Silence Therapeutics (SLN) Gross Margin (2024 - 2025)

Silence Therapeutics' Gross Margin history spans 2 years, with the latest figure at 64.71% for Q4 2025.

  • For Q4 2025, Gross Margin fell 2724.0% year-over-year to 64.71%; the TTM value through Dec 2025 reached 61.54%, down 1116.0%, while the annual FY2025 figure was 61.54%, 1116.0% down from the prior year.
  • Gross Margin for Q4 2025 was 64.71% at Silence Therapeutics, down from 76.0% in the prior quarter.
  • Across five years, Gross Margin topped out at 91.95% in Q4 2024 and bottomed at 340.87% in Q2 2024.